The present invention relates to an adenosine A.sub.3 receptor ligand of the general formula (I), within those preferably to the antagonists, including a salt, solvate or isomer (tautomer, desmotrop, and optically active isomer) thereof, to a pharmaceutical composition containing the ligand, to the use of the ligand, to its preparation, and intermediates of the ligand of the general formula (II''), (III''), (IV''), (V''), (VI''), (VII''), (VIII'') and (XIII'') and their preparation.